KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for…
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet…
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) has announced its financial results for the second quarter and six months ending June 30, 2024, along with a corporate update. CEO Michael…
Prothena Corporation plc (NASDAQ:PRTA), a leader in protein dysregulation-based therapies, reported its financial results for Q2 and the first half of 2024, alongside key business updates. Second Quarter and 2024…
Verastem Oncology, a biopharmaceutical firm dedicated to developing new cancer treatments, has provided an update on its business activities and financial performance for the second quarter ended June 30, 2024.…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapies from its boron chemistry platform, today announced topline results from the Phase 2 portion of the…
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical firm specializing in innovative non-opioid pain treatments, has unveiled new positive clinical data for vocacapsaicin, its leading product candidate for managing postsurgical pain. The…
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced a partnership with…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the European Commission has granted Orphan Drug Designation to AMX0035, its proprietary fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for…
Agilent Technologies Inc. (NYSE: A) has announced FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced that the U.S. FDA has granted accelerated approval for TECELRA® (afamitresgene autoleucel) as the first engineered cell therapy for treating solid tumors. This…
Novaliq, a biopharmaceutical company specializing in innovative ocular therapies using EyeSol® waterless technology, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued…